HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Parabens Potential Estrogenic Activity Examined By CTFA/Colipa

This article was originally published in The Rose Sheet

Executive Summary

The Cosmetic, Toiletry and Fragrance Association and Colipa are working jointly to devise a plan to address the potential endocrine and male reproductive effects of parabens, CTFA Director-Safety & Regulatory Toxicology Linda Loretz, PhD, told the association's Science Executive Leadership Conference in Charleston, S.C. April 18-20

You may also be interested in...



Paraben Link To Breast Cancer Unproven By Data, EU SCCP Says

Demonstrable evidence does not exist to link breast cancer to the use of underarm cosmetics containing parabens, the EU's Scientific Committee on Consumer Products concluded in an opinion issued Jan. 28 and recently posted on its Web site

Paraben Link To Breast Cancer Unproven By Data, EU SCCP Says

Demonstrable evidence does not exist to link breast cancer to the use of underarm cosmetics containing parabens, the EU's Scientific Committee on Consumer Products concluded in an opinion issued Jan. 28 and recently posted on its Web site

CIR To Consider New Data On Retinol During 2005 Review

The Cosmetic Ingredient Review Expert Panel plans to re-review retinol and retinyl palmitate during a meeting in June, the panel announced. CIR last reviewed the ingredients in 1987, concluding they are safe for use in cosmetics in concentrations up to 5%

Related Content

Latest News
UsernamePublicRestriction

Register

RS012100

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel